Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Mefloquine hydrochloride
Drug ID BADD_D01370
Description Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019.[L30618] Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin.[L30623] Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976. It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche.[A226838] This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]
Indications and Usage For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
Marketing Status Prescription; Discontinued
ATC Code P01BC02
DrugBank ID DB00358
KEGG ID D00831
MeSH ID D015767
PubChem ID 40692
TTD Drug ID D0GQ7K
NDC Product Code 0054-0025; 17381-840; 50090-2396; 17337-0528; 68071-4702; 0555-0171
Synonyms Mefloquine | Mephloquine | WR-177,602 | WR 177,602 | WR177,602 | Ro-21-5998-001 | Ro 21 5998 001 | Ro215998001 | WR-142,490 | WR 142,490 | WR142,490 | Lariam | Mefloquine Hydrochloride
Chemical Information
Molecular Formula C17H16F6N2O
CAS Registry Number 51742-87-1
SMILES C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Haematocrit decreased13.01.05.001--Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate irregular13.14.04.003--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Insomnia19.02.01.002; 17.15.03.002--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.001--Not Available
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Palpitations02.01.02.003--
Panic attack19.06.04.001--Not Available
Paraesthesia17.02.06.005--
Paranoia19.05.01.005--Not Available
Pneumonitis22.01.01.006--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Restlessness17.02.05.021; 19.11.02.002--
Seizure17.12.03.001--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages